Display options
Cite
Zubkov MR, Waldman RA, Wu R, et al. Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants. Cutis. 2021;108(4):199-200doi: 10.12788/cutis.0366.
Zubkov, M. R., Waldman, R. A., Wu, R., & Grant-Kels, J. M. (2021). Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants. Cutis, 108(4), 199-200. https://doi.org/10.12788/cutis.0366
Zubkov, Micaella R, et al. "Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants." Cutis vol. 108,4 (2021): 199-200. doi: https://doi.org/10.12788/cutis.0366
Zubkov MR, Waldman RA, Wu R, Grant-Kels JM. Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants. Cutis. 2021 Oct;108(4):199-200. doi: 10.12788/cutis.0366. PMID: 34846999.
Copy Download .nbib Format: NLM
Share it on

Cutis. 2021 Oct;108(4):199-200. doi: 10.12788/cutis.0366.

Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants.

Cutis

Micaella R Zubkov, Reid A Waldman, Rong Wu, Jane M Grant-Kels

Affiliations

  1. Dr. Zubkov is from the University of Connecticut School of Medicine, Farmington. Drs. Waldman and Grant-Kels are from the Department of Dermatology, University of Connecticut Health Center, Farmington. Dr. Grant-Kels also is from the Department of Dermatology, University of Florida, Gainesville. Dr. Wu is from the Connecticut Convergence Institute for Translation in Regenerative Engineering, University of Connecticut, Farmington.

PMID: 34846999 DOI: 10.12788/cutis.0366

[No abstract available.]

Publication Types